ENVERIC BIOSCIENCES, INC. Revenue from Contract with Customer, Excluding Assessed Tax
ENVERIC BIOSCIENCES, INC. (ENVB) reported Revenue from Contract with Customer, Excluding Assessed Tax of $8.48 million for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-11-16.
Discontinued › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2020-11-16
- ENVERIC BIOSCIENCES, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2020-09-30 was $8.48M, a 7.28% decline year-over-year.
- ENVERIC BIOSCIENCES, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2020-06-30 was $8.25M, a 25.06% decline year-over-year.
- ENVERIC BIOSCIENCES, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2019-12-31 was $9.06M.
- ENVERIC BIOSCIENCES, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2019-09-30 was $9.15M.
- ENVERIC BIOSCIENCES, INC. revenue from contract with customer, excluding assessed tax for fiscal 2019 was $39.91M, a 7.17% decline from fiscal 2018.
- ENVERIC BIOSCIENCES, INC. revenue from contract with customer, excluding assessed tax for fiscal 2018 was $43.00M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2020-09-30 | $8.48M 10-Q · filed 2020-11-16 | $16.74M derived: sum of 2 quarters · filed 2020-11-16 | $26.34M 10-Q · filed 2020-11-16 | |
| 2020-06-30 | $8.25M 10-Q · filed 2020-08-14 | $17.86M 10-Q · filed 2020-08-14 | ||
| 2019-12-31 | $9.06M derived: 10-K/A 12 month − 10-Q 9 month · filed 2020-08-12 | $18.21M derived: sum of 2 quarters · filed 2020-11-16 | $29.23M derived: sum of 3 quarters · filed 2020-11-16 | $39.91M 10-K/A · filed 2020-08-12 |
| 2019-09-30 | $9.15M 10-Q · filed 2020-11-16 | $20.16M derived: sum of 2 quarters · filed 2020-11-16 | $30.85M 10-Q · filed 2020-11-16 | |
| 2019-06-30 | $11.02M 10-Q · filed 2020-08-14 | $21.70M 10-Q · filed 2020-08-14 | ||
| 2018-12-31 | $43.00M 10-K/A · filed 2020-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |